Gynecologic Cancer

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Study Purpose: To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.

Status: Suspended

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research

Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.

Status: Suspended

Official Title: A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

Study Purpose: To understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.

Status: Recruiting

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial  

Study Purpose: To investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis and/or extracapsular extension in the SN.

Status: Recruiting

Official Title: Testing the addition of Herceptin Hylecta or Phesgo to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma.

Study Purpose: To determine if the addition of the study drugs will lower the chance of this disease from coming back.

Status: Recruiting

Official Title: A Randomized Phase II Trial of Nivolumab and Ipilimumab compared to Nivolumab Monotherapy in patients with deficient mismatch repair system recurrent endometrial carcinoma.

Study Purpose: To find out if combining two immunotherapy drugs, nivolumab and ipilimumab, is better or worse than the usual approach with a single immunotherapy agent.

Status: Recruiting

Official Title: A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER)

Study Purpose: To determine if there are types of early-stage endometrial cancer that require less post-surgical treatment than the usual approach.

Status: Recruiting

Official Title: A PHASE III TRIAL OF ONE VS. TWO YEARS OF MAINTENANCE OLAPARIB, WITH OR WITHOUT BEVACIZUMAB, IN PATIENTS WITH BRCA1/2 MUTATED OR HOMOLOGOUS RECOMBINATION DEFICIENT (HRD+) OVARIAN CANCER FOLLOWING RESPONSE TO FIRST LINE PLATINUM-BASED CHEMOTHERAPY

Study Purpose: To study if the use of Olaparib for one year keeps your ovarian cancer from growing or returning as well as the usual approach of two years.

Status: Recruiting

Official Title: A Phase III study of induction pembrolizumab and chemotherapy followed by pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer

Study Purpose: To find out if adding an immunotherapy drug plus chemotherapy before starting the usual combination of chemotherapy and radiation will increase overall survival or improve recurrence-free survival from cervical cancer.

Status: Recruiting